Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 8/2021

01-08-2021 | Multiple Sclerosis | Original Article

Superoxide dismutase (SOD), advanced oxidation protein products (AOPP), and disease-modifying treatment are related to better relapse recovery after corticosteroid treatment in multiple sclerosis

Authors: Dragana Obradovic, Tamara Andjelic, Milica Ninkovic, Bratislav Dejanovic, Jelena Kotur-Stevuljevic

Published in: Neurological Sciences | Issue 8/2021

Login to get access

Abstract

Objectives

The aim of our study was to analyze oxidative stress (OS) markers in multiple sclerosis (MS) patients during relapse and remission and to evaluate the effects of corticosteroid relapse treatment on oxidative status, and also to determine possible relationship between OS markers and relapse disability recovery after corticosteroid treatment.

Methods

Our study included 118 MS patients, (59 relapse/59 remission) 70 females and 48 males, mean age 40.2 ± 9.4 years, and 88 matched healthy controls. Undergoing disease-modifying therapy (DMT) was present in 30.5% of relapse and 88% of remission MS patients. We analyzed in plasma/serum the following: pro-oxidative–antioxidative balance (PAB), nitrates and nitrites (NO3 + NO2), malondialdehyde (MDA), advanced oxidation protein products (AOPP) superoxide dismutase (SOD), catalase (CAT), uric acid, bilirubin, albumin, and transferrin in all patients and additionally after corticosteroid relapse treatment. Neurological disability was measured using the Extended Disability Status Scale (EDSS).

Results

Better clinical recovery after relapse treatment was associated with increased baseline SOD, decreased AOPP, and ongoing DMT (all p < 0.05). There was no difference between OS markers in relapse and remission. MS patients had higher MDA, NO3 + NO2, PAB, SOD, CAT, lower AOPP, uric acid, albumin, bilirubin, and transferrin compared to controls (all p < 0.05). Corticosteroids caused significant decrease of all OS markers (all p < 0.05).

Conclusion

Increased baseline antioxidative activity of SOD and decreased baseline levels of pro-oxidant AOPP along with ongoing DMT were related to better clinical recovery after corticosteroid relapse treatment. Increase of pro-oxidants and antioxidant enzyme activity in relapse and remission confirms ongoing oxidative injury irrelevant of MS clinical presentation.
Appendix
Available only for authorised users
Literature
1.
Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, Rocca MA (2018) Multiple sclerosis. Nat Rev Dis Primers 4(1):43CrossRef
2.
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ et al (2014) Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83(3):278–286CrossRef
3.
Comi G, Radaelli M (2015) Oral corticosteroids for multiple sclerosis relapse. Lancet. 386(9997):937–939CrossRef
4.
Miller H, Newell D, Ridley A (1961) Multiple sclerosis: treatment of acute exacerbations with corticotrophin (ACTH). Lancet 2(7212):1120–1122CrossRef
5.
Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M (2001) Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 57(7):1239–1247CrossRef
6.
Milligan NM, Newcombe R, Compston DA (1987) A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 50(5):511–516CrossRef
7.
Obradović D, Kataranovski M, Dincić E, Obradović S, Colić M (2012) Tumor necrosis factor-alfa and interleukin-4 in cerebrospinal fluid and plasma in different clinical forms of multiple sclerosis. Vojnosanit Pregl 69(2):151–156CrossRef
8.
van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra CD, van der Valk P, de Vries HE (2008) Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med 45(12):1729–1737CrossRef
9.
Cobley JN, Fiorello ML, Bailey DM (2018) 13 reasons why the brain is susceptible to oxidative stress. Redox Biol 15:490–503CrossRef
10.
Mezzaroba L, Simao ANC, Oliveira SR, Flauzino T, Alfieri DF, de Carvalho Jennings Pereira WL, Kallaur AR, Lozovoy MAB, Kaimen-Maciel DR, Maes M, Reiche EMV (2020) Antioxidant and anti-inflammatory diagnostic biomarkers in multiple sclerosis: a machine learning study. Mol Neurobiol 57(5):2167–2178CrossRef
11.
Oliveira SR, Kallaur AP, Reiche EMV, Kaimen-Maciel DR, Panis C, Lozovoy MAB, Morimoto HK, Maes M, Dichi I, Simão ANC (2017) Albumin and protein oxidation are predictors that differentiate relapsing-remitting from progressive clinical forms of multiple sclerosis. Mol Neurobiol 54(4):2961–2968CrossRef
12.
Jovicic A, Jovanovic M, Djordjevic D, Magdic B, Dincic E, Malicevic Z (1997) Oxidative and antioxidative activity in the patients with disseminated demyelination disease of the central nervous system. Vojnosanit Pregl 54(3):193–202PubMed
13.
14.
Amorini AM, Petzold A, Tavazzi B, Eikelenboom J, Keir G, Belli A, Giovannoni G, Di Pietro V, Polman C, D’Urso S, Vagnozzi R, Uitdehaag B, Lazzarino G (2009) Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem 42(10–11):1001–1006CrossRef
15.
Toncev G, Milicic B, Toncev S, Samardzic G (2002) High-dose methylprednisolone therapy in multiple sclerosis increases serum uric acid levels. Clin Chem Lab Med 40(5):505–508CrossRef
16.
Keles M, Taysi S, Aksoy H, Sen N, Polat F, Akcay F (2001) The effects of the corticosteroids on serum and cerebrospinal fluid nitric oxide levels in multiple sclerosis. Clin Chem Lab Med 39(9):827–829CrossRef
17.
Mitosek-Szewczyk K, Gordon-Krajcer W, Walendzik P, Stelmasiak Z (2010) Free radical peroxidation products in cerebrospinal fluid and serum of patients with multiple sclerosis after glucocorticoid therapy. Folia Neuropathol 48(2):116–122PubMed
18.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the “McDonald Criteria”. Ann Neurol 69(2):292–302CrossRef
19.
Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurol 33(11):1444–1452CrossRef
20.
Girotti MJ, Khan N, McLellan BA (1991) Early measurement of systemic lipid peroxidation products in the plasma of major blunt trauma patients. J Trauma 31(1):32–35CrossRef
21.
Navarro-Gonzalez JA, Garcia-Benayas C, Arenas J (1998) Semiautomated measurement of nitrate in biological fluids. Clin Chem 44(3):679–681CrossRef
22.
Alamdari DH, Paletas K, Pegiou T, Sarigianni M, Befani C, Koliakos G (2007) A novel assay for the evaluation of the prooxidant-antioxidant balance, before and after antioxidant vitamin administration in type II diabetes patients. Clin Biochem 40(3–4):248–254CrossRef
23.
Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B (1996) Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49(5):1304–1313CrossRef
24.
Sun M, Zigman S (1978) An improved spectrophotometric assay for superoxide dismutase based on epinephrine autoxidation. Anal Biochem 90(1):81–89CrossRef
25.
Góth L (1991) A simple method for determination of serum catalase activity and revision of reference range. Clin Chim Acta 196(2–3):143–151CrossRef
26.
27.
Lublin FD, Cutter G, Giovannoni G, Pace A, Campbell NR, Belachew S (2014) Natalizumab reduces relapse clinical severity and improves relapse recovery in MS. Mult Scler Relat Disord 3(6):705–711CrossRef
28.
29.
Berridge MJ (2015) Vitamin D cell signaling in health and disease. Biochem Biophys Res Commun 460(1):53–71CrossRef
30.
Robledinos-Antón N, Fernández-Ginés R, Manda G, Cuadrado A (2019) Activators and inhibitors of NRF2: a review of their potential for clinical development. Oxid Med Cell Longev. 10.1155/2019/9372182. eCollection 2019
31.
32.
Acar G, Idiman F, Idiman E, Kirkali G, Cakmakçi H, Ozakbaş S (2003) Nitric oxide as an activity marker in multiple sclerosis. J Neurol 250(5):588–592CrossRef
33.
34.
Guerrero AL, Gutiérrez F, Iglesias F, Martín-Polo J, Merino S, Martín-Serradilla JI, Laherra’n SE, Tejero MA (2011) Serum uric acid levels in multiple sclerosis patients inversely correlate with disability. Neurol Sci 32(2):347–350CrossRef
35.
Burt MG, Johannsson G, Umpleby AM, Chisholm DJ, Ho KK (2007) Impact of acute and chronic low-dose glucocorticoids on protein metabolism. J Clin Endocrinol Metab 92(10):3923–3929CrossRef
36.
Oakley RH, Cidlowski JA (2011) Cellular processing of the glucocorticoid receptor gene and protein:new mechanisms for generating tissue-specific actions of glucocorticoids. J Biol Chem 286(5):3177–3184CrossRef
37.
Song IH, Buttgereit F (2006) Non-genomic glucocorticoid effects to provide the basis for new drug developments. Mol Cell Endocrinol 246(1–2):142–146CrossRef
38.
39.
Wang P, Xie K, Wang C, Bi J (2014) Oxidative stress induced by lipid peroxidation is related with inflammation of demyelination and neurodegeneration in multiple sclerosis. Eur Neurol 72(3–4):249–254CrossRef
Metadata
Title
Superoxide dismutase (SOD), advanced oxidation protein products (AOPP), and disease-modifying treatment are related to better relapse recovery after corticosteroid treatment in multiple sclerosis
Authors
Dragana Obradovic
Tamara Andjelic
Milica Ninkovic
Bratislav Dejanovic
Jelena Kotur-Stevuljevic
Publication date
01-08-2021
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 8/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-020-04928-y

Other articles of this Issue 8/2021

Neurological Sciences 8/2021 Go to the issue

Review Article

The efficacy of ultrasound-guided stellate ganglion block in alleviating postoperative pain and ventricular arrhythmias and its application prospects

Original Article

Early outcomes of migraine after erenumab discontinuation: data from a real-life setting

Letter to the Editor

A case of tauopathy with auditory agnosia and dysprosody diagnosed by [18F]PM-PBB3 tau PET scan

Original Article

Regular physical activity postpones age of occurrence of first-ever stroke and improves long-term outcomes

Original Article

Impaired pain processing and its association with attention disturbance in patients with amyotrophic lateral sclerosis

Original Article

Prediction of acute neurovascular syndromes with prehospital clinical features witnessed by bystanders